BRPI0811333A2 - "proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, célula, uso da proteína de fusão e composição farmacêutica" - Google Patents

"proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, célula, uso da proteína de fusão e composição farmacêutica"

Info

Publication number
BRPI0811333A2
BRPI0811333A2 BRPI0811333-5A BRPI0811333A BRPI0811333A2 BR PI0811333 A2 BRPI0811333 A2 BR PI0811333A2 BR PI0811333 A BRPI0811333 A BR PI0811333A BR PI0811333 A2 BRPI0811333 A2 BR PI0811333A2
Authority
BR
Brazil
Prior art keywords
fusion protein
vector
cell
pharmaceutical composition
dna sequence
Prior art date
Application number
BRPI0811333-5A
Other languages
English (en)
Inventor
Zheng Liu
Jianmin Fang
Original Assignee
Yantai Rongchang Biotechnologies Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yantai Rongchang Biotechnologies Co Ltd filed Critical Yantai Rongchang Biotechnologies Co Ltd
Publication of BRPI0811333A2 publication Critical patent/BRPI0811333A2/pt
Publication of BRPI0811333B1 publication Critical patent/BRPI0811333B1/pt
Publication of BRPI0811333B8 publication Critical patent/BRPI0811333B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
BRPI0811333A 2007-06-15 2008-06-16 proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, microrganismo transgênico, uso da proteína de fusão, e composição farmacêutica BRPI0811333B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2007101111622A CN101323643B (zh) 2007-06-15 2007-06-15 优化的TACI-Fc融合蛋白
CH200710111162.2 2007-06-15
PCT/CN2008/001162 WO2008154814A1 (fr) 2007-06-15 2008-06-16 PROTÉINES DE FUSION TACI-Fc OPTIMISÉES

Publications (3)

Publication Number Publication Date
BRPI0811333A2 true BRPI0811333A2 (pt) 2015-06-16
BRPI0811333B1 BRPI0811333B1 (pt) 2020-09-15
BRPI0811333B8 BRPI0811333B8 (pt) 2021-05-25

Family

ID=40155884

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811333A BRPI0811333B8 (pt) 2007-06-15 2008-06-16 proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, microrganismo transgênico, uso da proteína de fusão, e composição farmacêutica

Country Status (8)

Country Link
US (1) US8193316B2 (pt)
EP (1) EP2161287B1 (pt)
JP (1) JP5372917B2 (pt)
KR (1) KR101204229B1 (pt)
CN (1) CN101323643B (pt)
BR (1) BRPI0811333B8 (pt)
RU (1) RU2433141C2 (pt)
WO (1) WO2008154814A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201120210A (en) 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
AU2012204846B2 (en) * 2011-01-06 2016-09-08 Complix Nv Alphabodies specifically binding to cytokines or growth factors and/or cytokine or growth factor receptors
CN102085367B (zh) * 2011-01-19 2012-08-22 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白用于制备治疗类风湿性关节炎药物的应用
CN102085368B (zh) * 2011-01-19 2013-06-12 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用
CN103833856B (zh) * 2012-11-22 2017-05-03 上海康岱生物医药技术股份有限公司 抑制taci‑baff复合物形成的融合蛋白及其制法和用途
CN103936833B (zh) * 2014-04-18 2016-02-10 天津大学 BLyS拮抗肽、含TC-Fc融合蛋白基因的质粒及TC-Fc融合蛋白
EP3642243A4 (en) 2017-06-20 2021-04-28 Dana-Farber Cancer Institute, Inc. METHOD OF MODULATING REGULATORY T-CELLS, REGULATORY B-CELLS AND IMMUNE RESPONSIBILITIES USING MODULATORS OF APRIL-TACI INTERACTION
CN110522908A (zh) * 2018-05-25 2019-12-03 荣昌生物制药（烟台）有限公司 TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用
AU2020401160B2 (en) 2019-12-10 2024-11-14 Remegen Co., Ltd. Pharmaceutical TACI-Fc fusion protein formulation
KR20220034742A (ko) * 2019-12-24 2022-03-18 레메젠 코, 리미티드 Taci-fc 융합 단백질 및 그 용도
JP7748393B2 (ja) 2020-05-08 2025-10-02 アルパイン イミューン サイエンシズ インコーポレイテッド Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法
CN115073607A (zh) * 2021-03-12 2022-09-20 上海康岱生物医药技术股份有限公司 Tnfr2与baff受体的融合蛋白
JP2024514077A (ja) * 2021-03-31 2024-03-28 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 切断したｔａｃｉポリペプチド及びその融合タンパク質並びに使用
KR20240019124A (ko) 2021-05-07 2024-02-14 알파인 이뮨 사이언시즈, 인코포레이티드 Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법
WO2022258045A1 (zh) * 2021-06-11 2022-12-15 山东先声生物制药有限公司 抗人il-17抗体和taci的双功能融合蛋白分子
US20240002468A1 (en) 2021-08-10 2024-01-04 Remegen Co., Ltd. Method for treating iga nephropathy with taci-fc fusion protein
KR20240067099A (ko) * 2021-09-30 2024-05-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-il23 항체 융합 단백질 및 용도
AU2022358137B2 (en) * 2021-09-30 2026-02-12 Remegen Co., Ltd. Method for treating sjogren’s syndrome using taci-fc fusion protein
WO2023083298A1 (zh) * 2021-11-11 2023-05-19 江苏恒瑞医药股份有限公司 抗icosl抗体融合蛋白及用途
IL317055A (en) 2022-06-08 2025-01-01 Remegen Co Ltd METHOD FOR TREATING MYASTHENIA GRAVIS WITH TACI-FC FUSION PROTEIN
EP4582455A4 (en) * 2022-08-29 2026-03-25 Jiangsu Hengrui Pharmaceuticals Co Ltd Fusion protein comprising a Taci polypeptide and its use
JP2025532251A (ja) * 2022-09-30 2025-09-29 レメゲン シーオー．，エルティーディー． ＴＡＣＩ－Ｆｃ融合タンパク質を用いた膜性腎症の治療方法
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein
WO2024114777A1 (zh) * 2022-12-02 2024-06-06 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗微小病变型肾病的方法
EP4527375A1 (en) 2022-12-07 2025-03-26 RemeGen Co., Ltd. Taci-fc fusion protein liquid pharmaceutical preparation
JP2026510999A (ja) 2023-03-21 2026-04-10 バイオグラフ ５５，インク． Ｃｄ１９／ｃｄ３８多重特異性抗体
WO2025007943A1 (zh) 2023-07-06 2025-01-09 荣昌生物制药(烟台)股份有限公司 用taci-fc融合蛋白治疗anca相关性血管炎的方法
WO2025209465A1 (zh) * 2024-04-02 2025-10-09 福佑泰生物制药公司 Taci/bcma嵌合体融合蛋白及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004513876A (ja) * 2000-04-27 2004-05-13 バイオジェン　インコーポレーテッド 抗−腫瘍剤としてのｔａｃｉ
US20040013674A1 (en) * 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
BRPI0209933B8 (pt) * 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
RU2005141541A (ru) * 2003-06-05 2006-06-27 Дженентек, Инк. (Us) Комбинированная терапия в-клеточных нарушений
CA2585927A1 (en) * 2004-11-04 2006-05-18 Genentech, Inc. Polypeptides that bind baff and/or april
EP1922079A2 (en) * 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
CN100471872C (zh) * 2005-11-04 2009-03-25 余波 包含vegf受体片段的优化融合蛋白质及其医疗应用

Also Published As

Publication number Publication date
KR101204229B1 (ko) 2012-11-26
WO2008154814A1 (fr) 2008-12-24
JP5372917B2 (ja) 2013-12-18
EP2161287B1 (en) 2015-03-04
CN101323643A (zh) 2008-12-17
US8193316B2 (en) 2012-06-05
EP2161287A1 (en) 2010-03-10
KR20100009600A (ko) 2010-01-27
RU2433141C2 (ru) 2011-11-10
BRPI0811333B1 (pt) 2020-09-15
BRPI0811333B8 (pt) 2021-05-25
RU2009148020A (ru) 2011-07-10
JP2010529967A (ja) 2010-09-02
EP2161287A4 (en) 2010-08-11
CN101323643B (zh) 2010-12-01
US20100136008A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
BRPI0811333A2 (pt) "proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, célula, uso da proteína de fusão e composição farmacêutica"
BRPI0807480A2 (pt) Ligando, imunoglobulina g, composição e proteína de fusão
BRPI0806501A2 (pt) Proteína de fusão, molécula de ácido nucleico, vetor, célula hospedeira, vacina ou composição imunogênica, e, uso da proteína de fusão.
IL202443B (en) Nucleic acid encoding it and a pharmaceutical preparation containing the protein, a fusion protein for nucleic acid
IL205705A (en) Anti-influenza antibodies, compositions comprising the same and uses thereof
BRPI0716416A2 (pt) polipeptídeo substancialmente puro entre 37 e 47 besíduos de aminoácido de comprimento, ácido nucléico isolado, vetor: célula hospedeira e composição farmacêutica
IL187168A (en) Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
BRPI0814296A2 (pt) Polipeptídeo isolado, seqüência de nucleotídeos, vetor, célula hospedeira, e, uso do polipeptídeo, da seqüência de nucleotídeos, do vetor ou da célula hospedeira
BRPI0812400A2 (pt) Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade.
BRPI0810305A2 (pt) "vetor, molécula de ácido nucléico substancialmente isolada, célula hospedeira, composição farmacêutica, uso de uma molécula de ácido nucléico, uso de um vetor, uso de uma célula hospedeira e uso de uma composição"
EP2000483A4 (en) VEGF RECEPTOR FUSION PROTEIN AND APPLICATION THEREOF
EP2162472A4 (en) IMMUNOGLOBULIN FUSION PROTEIN
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
EP1947142A4 (en) MELTABLE PROPYLENE POLYMERIC COMPOSITION, MELTABLE FOIL AND USE THEREOF
EP2171460A4 (en) MATERIALS FOR DETECTING POLYNUCLEOTIDES AND METHOD FOR THEIR USE
BRPI0820270A2 (pt) Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular.
BRPI0821447A2 (pt) Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
BRPI1006368A2 (pt) proteína de fusão. molécula de ácido nucleico, vetor, célula modificada geneticamente, método para produção da proteína de fusão, usos da proteína de fusão, composição, método para preparação de uma composição, kits, método e uso da proteína de fusão
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
BRPI0716744A2 (pt) proteínas de fusão de albumina
DK2064334T3 (da) Aldehydtags, anvendelser deraf i site-specifik proteinmodificering
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
EP2086576B8 (en) H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
DK2219675T3 (da) Formuleringer for taci-immunglobulin-fusionsproteiner
EP2362877A4 (en) POLYNUCLEOTIDES CODING FOR HUMAN TRIM-CYP FUSION POLYPEPTIDE, COMPOSITIONS THEREOF, AND METHOD OF USE THEREOF

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF